Literature DB >> 23908358

Bim polymorphisms: influence on function and response to treatment in children with acute lymphoblastic leukemia.

Vincent Gagné1, Julie Rousseau, Malgorzata Labuda, Bahram Sharif-Askari, Ivan Brukner, Caroline Laverdière, Francesco Ceppi, Stephen E Sallan, Lewis B Silverman, Donna Neuberg, Jeffery L Kutok, Daniel Sinnett, Maja Krajinovic.   

Abstract

PURPOSE: Corticosteroids induce apoptosis in the malignant lymphoid cells and are critical component of combination therapy for acute lymphoblastic leukemia (ALL). Several genome-wide microarray studies showed major implication of proapoptotic Bim in mediating corticosteroid-related resistance in leukemia cells. EXPERIMENTAL
DESIGN: We investigated Bim gene polymorphisms and their association with childhood ALL outcome, and the mechanism underlying the observed finding.
RESULTS: Lower overall survival (OS) was associated with Bim C29201T located in Bcl-2 homology 3 (BH3) domain (P = 0.01). An association remained significant in multivariate model (P = 0.007), was more apparent in high-risk patients (P = 0.004) and patients treated with dexamethasone (P = 0.009), and was subsequently confirmed in the replication patient cohort (P = 0.03). RNA analysis revealed that C29201T affects generation of γ isoforms (γ1) that lack proapoptotic BH3 domain. The phenotypic effect was minor suggesting the influence of additional factors that may act in conjunction with Bim genotype. Combined analysis with Mcl gene polymorphism (G-486T) revealed profound reduction in OS in individuals with both risk genotypes (P < 0.0005 in discovery and P = 0.002 in replication cohort) and particularly in high-risk patients (P ≤ 0.008).
CONCLUSIONS: Increased expression of prosurvival Mcl1 and presence of Bim isoforms lacking proapoptotic function might explain marked reduction of OS in a disease and dose-dependent manner in ALL patients carrying Bim- and Mcl1-risk genotypes. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23908358      PMCID: PMC4128417          DOI: 10.1158/1078-0432.CCR-13-1215

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  54 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia.

Authors:  W J E Tissing; J P P Meijerink; M L den Boer; R Pieters
Journal:  Leukemia       Date:  2003-01       Impact factor: 11.528

3.  Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells.

Authors:  Alejo A Morales; Metin Kurtoglu; Shannon M Matulis; Jiangxia Liu; David Siefker; Delia M Gutman; Jonathan L Kaufman; Kelvin P Lee; Sagar Lonial; Lawrence H Boise
Journal:  Blood       Date:  2011-06-09       Impact factor: 22.113

4.  Germline variation in apoptosis pathway genes and risk of non-Hodgkin's lymphoma.

Authors:  Jennifer L Kelly; Anne J Novak; Zachary S Fredericksen; Mark Liebow; Stephen M Ansell; Ahmet Dogan; Alice H Wang; Thomas E Witzig; Timothy G Call; Neil E Kay; Thomas M Habermann; Susan L Slager; James R Cerhan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-09-20       Impact factor: 4.254

5.  Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia.

Authors:  Jitesh D Kawedia; Sue C Kaste; Deqing Pei; John C Panetta; Xiangjun Cai; Cheng Cheng; Geoffrey Neale; Scott C Howard; William E Evans; Ching-Hon Pui; Mary V Relling
Journal:  Blood       Date:  2010-12-10       Impact factor: 22.113

Review 6.  Acute lymphoblastic leukaemia.

Authors:  Ching-Hon Pui; Leslie L Robison; A Thomas Look
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321

7.  Divergent mechanisms of glucocorticoid resistance in experimental models of pediatric acute lymphoblastic leukemia.

Authors:  Petra S Bachmann; Rosemary Gorman; Rachael A Papa; Jane E Bardell; Jette Ford; Ursula R Kees; Glenn M Marshall; Richard B Lock
Journal:  Cancer Res       Date:  2007-05-01       Impact factor: 12.701

8.  Polymorphisms in glucocorticoid receptor gene and the outcome of childhood acute lymphoblastic leukemia (ALL).

Authors:  Malgorzata Labuda; Annabel Gahier; Vincent Gagné; Albert Moghrabi; Daniel Sinnett; Maja Krajinovic
Journal:  Leuk Res       Date:  2009-09-16       Impact factor: 3.156

9.  Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis.

Authors:  Jie Han; Leslie A Goldstein; Brian R Gastman; Hannah Rabinowich
Journal:  J Biol Chem       Date:  2006-02-13       Impact factor: 5.157

10.  The SWI/SNF chromatin-remodeling complex and glucocorticoid resistance in acute lymphoblastic leukemia.

Authors:  Nicolas Pottier; Wenjian Yang; Mahfoud Assem; John C Panetta; Deqing Pei; Steven W Paugh; Cheng Cheng; Monique L Den Boer; Mary V Relling; Rob Pieters; William E Evans; Meyling H Cheok
Journal:  J Natl Cancer Inst       Date:  2008-12-09       Impact factor: 13.506

View more
  9 in total

Review 1.  [Association between BIM gene and glucocorticoid resistance in children with acute lymphoblastic leukemia].

Authors:  Jin-Yun Xu; Jian-Ming Luo
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2017-08

2.  ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure.

Authors:  Justine E Marum; David T Yeung; Leanne Purins; John Reynolds; Wendy T Parker; Doris Stangl; Paul P S Wang; David J Price; Jonathan Tuke; Andreas W Schreiber; Hamish S Scott; Timothy P Hughes; Susan Branford
Journal:  Blood Adv       Date:  2017-07-31

3.  Genes identified through genome-wide association studies of osteonecrosis in childhood acute lymphoblastic leukemia patients.

Authors:  Vincent Gagné; Anne Aubry-Morin; Maria Plesa; Rachid Abaji; Kateryna Petrykey; Pascal St-Onge; Patrick Beaulieu; Caroline Laverdière; Nathalie Alos; Jean-Marie Leclerc; Stephen E Sallan; Donna Neuberg; Jeffery L Kutok; Lewis B Silverman; Daniel Sinnett; Maja Krajinovic
Journal:  Pharmacogenomics       Date:  2019-11-05       Impact factor: 2.533

4.  Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.

Authors:  Seong Lin Khaw; Santi Suryani; Kathryn Evans; Jennifer Richmond; Alissa Robbins; Raushan T Kurmasheva; Catherine A Billups; Stephen W Erickson; Yuelong Guo; Peter J Houghton; Malcolm A Smith; Hernan Carol; Andrew W Roberts; David C S Huang; Richard B Lock
Journal:  Blood       Date:  2016-06-24       Impact factor: 22.113

5.  Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia.

Authors:  Francesco Ceppi; Chloé Langlois-Pelletier; Vincent Gagné; Julie Rousseau; Claire Ciolino; Samanta De Lorenzo; Kojok M Kevin; Diana Cijov; Stephen E Sallan; Lewis B Silverman; Donna Neuberg; Jeffery L Kutok; Daniel Sinnett; Caroline Laverdière; Maja Krajinovic
Journal:  Pharmacogenomics       Date:  2014-06       Impact factor: 2.533

Review 6.  Regulation of Bim in Health and Disease.

Authors:  Ronit Vogt Sionov; Spiros A Vlahopoulos; Zvi Granot
Journal:  Oncotarget       Date:  2015-09-15

Review 7.  A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer.

Authors:  Sheila X Soh; Fahad J Siddiqui; John C Allen; Go Woon Kim; Jae Cheol Lee; Yasushi Yatabe; Manabu Soda; Hiroyuki Mano; Ross A Soo; Tan-Min Chin; Hiromichi Ebi; Seiji Yano; Keitaro Matsuo; Xiaomin Niu; Shun Lu; Kazutoshi Isobe; Jih-Hsiang Lee; James C Yang; Mingchuan Zhao; Caicun Zhou; June-Koo Lee; Se-Hoon Lee; Ji Yun Lee; Myung-Ju Ahn; Tira J Tan; Daniel S Tan; Eng-Huat Tan; S Tiong Ong; Wan-Teck Lim
Journal:  Oncotarget       Date:  2017-06-20

8.  Identification of cis-acting elements and splicing factors involved in the regulation of BIM Pre-mRNA splicing.

Authors:  Wen Chun Juan; Xavier Roca; S Tiong Ong
Journal:  PLoS One       Date:  2014-04-17       Impact factor: 3.240

9.  Multi-agent chemotherapy overcomes glucocorticoid resistance conferred by a BIM deletion polymorphism in pediatric acute lymphoblastic leukemia.

Authors:  Sheila Xinxuan Soh; Joshua Yew Suang Lim; John W J Huang; Nan Jiang; Allen Eng Juh Yeoh; S Tiong Ong
Journal:  PLoS One       Date:  2014-08-04       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.